anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: The advances of minimally invasive endoscopy-guided procedures that usually yield limited diagnostic material changed pancreaticobiliary cytopathology into one of the most challenging areas of cytopathology given the abundance of differential diagnoses to be considered when dealing with limited specimens.
CASE PRESENTATION: We describe a few challenging examples of potential pitfalls in pancreatobiliary cytopathology evaluation collected from a busy academic hospital (tertiary) center. Case 1 illustrates the challenges in handling paucicellular specimens from pancreatic solid lesions in which differential diagnoses may include acinar cell carcinoma, neuroendocrine tumors, adenocarcinoma, or even benign pancreatic tissue, among others. Case 2 illustrates the pitfalls in evaluating limited specimens from patients with chronic pancreatitis, specially when distinguishing exuberant reactive atypia from dysplastic changes is mandatory. Case 3 illustrates pitfalls in distinguishing malignancy from reactive changes in biliary brushing specimens from patients with primary sclerosing cholangitis. Finally, cases 4 and 5 highlight the importance of including the possibility of pancreatic metastasis in the differential diagnoses of some pancreatic lesions.
CONCLUSION: Over time, there has been an increasing demand for pathologists to render diagnoses on limited specimens obtained through minimally invasive procedures which can be frequently challenging even for the most experienced professionals. In many difficult cases, salvaging additional material for a cell block can turn out to be extremely helpful given the possibility of utilizing additional ancillary tests for diagnostic confirmation.
Understanding the complex effects of genetic perturbations on cellular state and fitness in human pluripotent stem cells (hPSCs) has been challenging using traditional pooled screening techniques which typically rely on unidimensional phenotypic readouts. Here, Applicants use barcoded open reading frame (ORF) overexpression libraries with a coupled single-cell RNA sequencing (scRNA-seq) and fitness screening approach, a technique we call SEUSS (ScalablE fUnctional Screening by Sequencing), to establish a comprehensive assaying platform. Using this system, Applicants perturbed hPSCs with a library of developmentally critical transcription factors (TFs), and assayed the impact of TF overexpression on fitness and transcriptomic cell state across multiple media conditions. Applicants further leveraged the versatility of the ORF library approach to systematically assay mutant gene libraries and also whole gene families. From the transcriptomic responses, Applicants built genetic co-perturbation networks to identify key altered gene modules. Strikingly, we found that KLF4 and SNAI2 have opposing effects on the pluripotency gene module, highlighting the power of this method to characterize the effects of genetic perturbations. From the fitness responses, Applicants identified ETV2 as a driver of reprogramming towards an endothelial-like state.
This application provides methods to differentiate between subjects with autism spectrum disorder (ASD) and typically developing (TD) or developmentally delayed (DD) subjects using miRNA and/or microbiome levels detected in saliva samples and patient information. The method can be used to monitor the progress of ASD and guide its treatment. RNA-seq, qPCR, or other methods determine counts and abundance of miRNA or microbiomes. MicroRNA and/or microbiome sequencing data are refined by normalization to expression levels or abundance of time-invariant miRNAs and/or microbial RN As to control for time of sample collection or to compensate for circadian fluctuations in these levels. Multivariate logistic regression and nonlinear classification techniques are further used to select a panel of miRNAs and microbiomes that accurately differentiate between subjects with ASD, DD, and TD in subjects with an unknown ASD status. These panels of miRNAs and microbiomes may be developed into a RNA assay kit.
Lamivudine with adefovir combination therapy has been known as effective antiviral therapy for lamivudine resistant chronic hepatitis B patients. It is superior to adefovir monotherapy since the incidence of viral breakthrough of combination therapy used to be less than that of adefovir monotherapy in lamivudine resistant chronic hepatitis B patients. Clevudine, which is being marketed in Korea, is a nucleoside analogue of the unnatural beta-L configuration that has potent activity against HBV. It has demonstrated potent antiviral efficacy and significant biochemical improvement after 24 weeks of therapy. We hypothesized that clevudine plus adefovir combination therapy for lamivudine resistant patients might be as effective as the lamivudine plus adefovir combination therapy.

In detail, we designed to perform this clinical study comparing the combination of clevudine and adefovir with lamivudine plus adefovir in lamivudine resistant chronic hepatitis B patient. Total treatment duration of both groups will be 12 months, and compare the efficacy of antiviral effects of these drugs.
BACKGROUND: An exuberant and dysregulated inflammatory response contributes to the development and progression of cardiovascular diseases (CVDs).
METHODS: This narrative review includes original articles and reviews published over the past 20 years and found through PubMed. The following search terms (or combination of terms) were considered: "acute pericarditis," "recurrent pericarditis," "myocarditis," "cardiac sarcoidosis," "atherosclerosis," "acute myocardial infarction," "inflammation," "NLRP3 inflammasome," "Interleukin-1" and "treatment."
RESULTS: Recent evidence supports the role of inflammation across a wide spectrum of CVDs including myocarditis, pericarditis, inflammatory cardiomyopathies (i.e. cardiac sarcoidosis) as well as atherosclerotic CVD and heart failure. Interleukins (ILs) are the signalling mediators of the inflammatory response. The NACHT, leucine-rich repeat and pyrin-domain containing protein 3 (NLRP3) inflammasome play a key role in producing IL-1β, the prototypical pro-inflammatory cytokine involved in CVDs. Other pro-inflammatory cytokines (e.g. tumour necrosis factor) have been implicated in cardiac sarcoidosis. As a proof of this, IL-1 blockade has been proven efficacious in pericarditis and chronic coronary syndrome.
CONCLUSION: Tailored strategies aiming at quenching the inflammatory response have emerged as promising to treat CVDs. In this review article, we summarize recent evidence regarding the role of inflammation across a broad spectrum of CVDs. We also review novel evidence regarding targeted therapeutic strategies.
A mechanism for generating information usable for identifying a risk of arrhythmia. A plurality of heart models are constructed from medical imaging data of a subject's heart. each heart model being defined by a set of different values for one or more modifiable properties. The modifiable properties are those used in the generation of the heart model or in the definition of the heart model, and influence or affect simulation results using the heart model. Each heart model undergoes a plurality of simulations, each simulation being a simulation of a response of the heart model to a (simulated) stimulation of electricity at a different pacing location of the heart. Output data is generated containing indicators of all simulation results.
RTA 744 is a novel, anthracycline that has shown the ability to circumvent ATP-binding cassette transporters (Multidrug Resistance Protein 1, Breast Cancer Resistance Protein, P-glycoprotein) in vitro. This action enables RTA 744 to penetrate across the blood brain barrier. In a Phase I safety study, RTA 744 was shown to be generally well tolerated in patients with recurrent glioblastoma multiforme (GBM). Additionally, anti-tumor activity was observed. Breast cancer is known to be sensitive to anthracycline therapy. Based on the preliminary Phase I clinical results and the sensitivity of breast cancer to anthracycline therapy, this Phase II study will investigate the safety and efficacy of RTA 744 in patients with breast cancer and metastatic disease to the brain which has progressed following whole brain irradiation.

Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
The invention discloses a medicine used for stopping pain and curing rheumatism. The medicine comprises the Chinese traditional medicines and lyoenzymes which are prepared by the weight proportions: 7 to 40 of schcfflera arhoricola hayata, 20 to 120 of clematis root and 1000 to 4000 of liquor. The medicine also can be added with 15 to 90 of kadsura pepper stem, 15 to 90 of ovientvine, 15 to 90 of longhairy antenoron herb, 10 to 60 of angelica, 4 to 24 of schisandra propinqua and 16 to 96 of radix angelicae pubescentis. A preparation method of the medicine comprises the steps that: the liquor is firstly prepared and is put inside a container; all the Chinese traditional medicine components are milled to rough powders which are evenly mixed and put a closed container, and then are heated and extracted for three times together with the liquor with 2 hours for the first time, one hour for the second time and 0.5 hour for the third time. All the effective components of the medicine are nontoxic; besides, the invention has the functions of stopping pain and curing, with excellent effect, achieving completely radical treatment. The invention has the advantages of simple production technology, easy operation and low cost.
A flow control system and method of detecting a condition of a pump set mounted on the apparatus. The system configured to perform the method of advancing a first amount of the feeding formula through the feeding pump via a feeding formula conduit. Further, the system may acquire a first pressure sensor reading of the feeding formula conduit. Further, the system may advance a second amount of the feeding formula through the feeding pump via the feeding formula conduit, wherein the second amount is second volume of the liquid. Further, the system may acquire a second pressure sensor reading of the feeding formula conduit, and acquire a third pressure sensor reading of the feeding formula conduit. Further, the system may detect an occlusion in the feeding formula conduit based on at least one of the first pressure sensor reading, the second pressure sensor reading and the third pressure sensor reading.
Low frequency 1 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered continuously.
After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
Dry eye disease (DED) is currently the most prevalent condition seen in ophthalmology outpatient clinics, representing a significant public health issue. The onset and progression of DED are closely associated with oxidative stress-induced inflammation and damage. To address this, an aldehyde-functionalized F127 (AF127) hydrogel eye drop delivering multifunctional antioxidant Cu2-xSe nanoparticles (Cu2-xSe NPs) was designed. The research findings revealed that the Cu2-xSe nanoparticles exhibit unexpected capabilities in acting as superoxide dismutase and glutathione peroxidase. Additionally, Cu2-xSe NPs possess remarkable efficacy in scavenging reactive oxygen species (ROS) and mitigating oxidative damage. Cu2-xSe NPs displayed promising therapeutic effects in a mouse model of dry eye. Detailed investigation revealed that the nanoparticles exert antioxidant, anti-apoptotic, and inflammation-mitigating effects by modulating the NRF2 and p38 MAPK signalling pathways. The AF127 hydrogel eye drops exhibit good adherence to the ocular surface through the formation of Schiff-base bonds. These findings suggest that incorporating antioxidant Cu2-xSe nanoparticles into a tissue-adhesive hydrogel could present a highly effective therapeutic strategy for treating dry eye disease and other disorders associated with reactive oxygen species. STATEMENT OF SIGNIFICANCE: A new formulation for therapeutic eye drops to be used in the treatment of dry eye disease (DED) was developed. The formulation combines copper-selenium nanoparticles (Cu2-xSe NPs) with aldehyde-functionalized Pluronic F127 (AF127). This is the first study to directly examine the effects of Cu2-xSe NPs in ophthalmology. The NPs exhibited antioxidant capabilities and enzyme-like properties. They effectively eliminated reactive oxygen species (ROS) and inhibited apoptosis through the NRF2 and p38 MAPK signalling pathways. Additionally, the AF127 hydrogel enhanced tissue adhesion by forming Schiff-base links. In mouse model of DED, the Cu2-xSe NPs@AF127 eye drops demonstrated remarkable efficacy in alleviating symptoms of DED. These findings indicate the potential of Cu2-xSe NPs as a readily available and user-friendly medication for the management of DED.
Respiratory muscle training with the Orygen-Dual Valve (Forumed S.L. ESP) and an initial load of 30% of their maximum inspiratory and expiratory pressures.
Lipo-protein-free, hepatitis-virus-free, fibrinogen-free stable and sterile serum is prepared by intimately mixing blood serum or blood plasma with 250 to 545 mg of colloidal silicic acid per gram of total protein in the serum and, after separating the silicic acid containing lipoproteins and fibrinogen, irradiating the serum with U.V. light and then filtering sterile or vice versa.  The process may be carried out at up to 50 DEG C. with a pH range of 6.5 to 8 and U.V. irradiation intensity of 1 milliwatt/cm2 minute.  The sterile filtration is preferably interposed between the adsorbtion operation and the U.V. irradiation and may involve using asbestos-containing filters impervious to bacteria with a pore diameter of 0.9 to 1.2m or a milli pore sieve membrane with a pore diameter of 0.22m  \sB 10%. The silicic acid precipitate may be treated with concentrated salt solutions in the alkaline pH range (preferably saturated Na Cl solution at pH 9.0) to obtain a lipoprotein solution.
No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
PURPOSE:To obtain the titled preparation having excellent local affinity, controlling action on release of drug, capable of maintaining medicinal effects for a long time, by dispersing particles of a high polymer of specific properties into a water-soluble high polymer. CONSTITUTION:One or more of ophthalmic remedying active substances (e.g. beta-adrenergic blocker such as timolol or befunolol) are dispersed into a base for preparation. The base is obtained by dispersing granules comprising a water- insoluble high polymer (e.g. methyl cellulose), a high polymer (e.g. polyglycolic acid) decomposable in organisms or a high polymer soluble in a limited pH range (soluble at pH 4-6) into a water-soluble high polymer. In pharmaceutical preparation, the dispersion is molded into a filmy, sheet-like or disclike solid substance or a gelatinous or ointment semisolid.
Calcification is an essential part of all atherosclerotic plaques. Its extent increases with the progression of atherosclerotic disease. Heavily calcified lesions form a particular threat to DES; both damage to the polymer coating during vigorous advancement and inadequate diffusion of the drug to the subintima through extensive calcium arcs could contribute to the ineffectiveness of DES when implanted into such lesions, or may lead to primary stent delivery or expansion failure. Rotational atherectomy can effectively ablate calcified plaques. In the DES era, data concerning rotational atherectomy are scarce. DES implantation following rotablation seems a rational combination, but is only poorly supported by controlled studies. In the present study, we are using the polymer-based slow-release paclitaxel-eluting stent (TAXUS; Boston Scientific), with or without prior rotablation, in an angiographically well defined group of patients with complex calcified coronary lesions. This prospective, randomized, controlled study aims at evaluating the long term effects of both strategies in this complex cohort of patients.
TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective "Eyeball test", Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced.
In a bacteriological examination system, an expected range of drug sensitivity is calculated from the results of statistics of data acquired at past drug sensitivity tests. Testing panels accommodating drugs of different densities (ex. increasing by increments) covers the calculated expected range are selected for testing. An average-per-sample value of drug sensitivities of bacteria that reside in a hospital and an average-per-sample value of drug sensitivities of bacteria that reside in a limited region are preserved separately in a results-of-test database. A difference between statistical values of drug sensitivities of one bacterial species in a bacterial classification group residing in a hospital to an object drug and statistical values of drug sensitivities of the bacterial species residing in a limited region is calculated. The difference then is divided by the average-per-same value in the limited region. An average-per-bacterial species value is then obtained by averaging the difference-division values of the involved species to obtain a drug fastness index relative to the object drug.
PURPOSE: To obtain a UV absorber containing as an active ingredient a chlorogenic acid homologue and/or coffeic acid which are high in safety and stability and which have an excellent durable UV light-absorbing ability. CONSTITUTION: The UV absorber contains a chlorogenic acid homologue such as chlorogenic acid, neochlorogenic acid, band-510, isochlorogenic acid and/or coffeic acid as an active ingredient. Further, the skin external agent, especially a photooxidation-proofing skin external agent, contains the UV absorber. The UV absorber can be expected to have effects for preventing the sunburn of skin due to UV light, preventing the stimulation of aging due to the irradiation of the light, and preventing the generation of stains, freckles, fine wrinkles, etc., due to the photooxidation of the skin, and further to have a beautifying effect. The chlorogenic acid derivative originated from natural substances is contained as the chlorogenic acid, the neochlorogenic acid, the band-510, the isochlorogenic acid, etc., in e.g. coffee beans.  The coffeic acid is contained in needle-leaf tree barks, Polygonaceae plants, tobacco, etc., in a free state, but is obtained as the chlorogenic acid from the coffee beans, etc.
Recurrent respiratory papillomatosis is a chronic infection of the airway mucosa by the human papilloma virus, in the form of recurrent exophytic papilloma. Two clinical forms are distinguished: juvenile and adult onset. Depending on their size and location, papilloma can cause dysphonia, pharyngeal discomfort, until obstruction of the airway. There is no curative treatment. The management strategy is to surgically remove symptomatic disease by transoral approach, but some recurrent disease require multiple interventions and -adjuvant therapies. The symptoms caused by the disease as well as treatments' side effects have a major impact on patient's quality of life. Vaccination against HPV currently represents the best strategy to prevent disease.
Patients, aged 18 to 75 years, with diagnosis of unilateral tibial fracture, complicated by Acute Compartment syndrome and/or acute vascular compromise (leg ischemia, absent pulses below the knee), as diagnosed and confirmed by ED physician, orthopedic surgeon and/or vascular surgeon. Only patients with depth to anterior compartment \<2.5 cm as measured by the ultrasound will be enrolled.
The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments, the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. In alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI.
A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels \> 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels \> 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to \< 10.6 mg/dL and/or \<7.1 mg/dL respectively.
There is an intrinsic relationship between psychiatric disorders and neuroinflammation, including bipolar disorder. Ouabain, an inhibitor of Na+/K+-ATPase, has been implicated in the mouse model with manic-like behavior. However, the molecular mechanisms linking neuroinflammation and manic-like behavior require further investigation. CCAAT/Enhancer-Binding Protein Delta (CEBPD) is an inflammatory transcription factor that contributes to neurological disease progression. In this study, we demonstrated that the expression of CEBPD in astrocytes was increased in ouabain-treated mice. Furthermore, we observed an increase in the expression and transcript levels of CEBPD in human primary astrocytes following ouabain treatment. Transcriptome analysis revealed high MMP8 expression in human primary astrocytes following CEBPD overexpression and ouabain treatment. We confirmed that MMP8 is a CEBPD-regulated gene that mediates ouabain-induced neuroinflammation. In our animal model, treatment of ouabain-injected mice with M8I (an inhibitor of MMP8) resulted in the inhibition of manic-like behavior compared to ouabain-injected mice that were not treated with M8I. Additionally, the reduction in the activation of astrocytes and microglia was observed, particularly in the hippocampal CA1 region. Excessive reactive oxygen species formation was observed in ouabain-injected mice, and treating these mice with M8I resulted in the reduction of oxidative stress, as indicated by nitrotyrosine staining. These findings suggest that MMP8 inhibitors may serve as therapeutic agents in mitigating manic symptoms in bipolar disorder.